grace targeted therapies lung cancer 2021 - single agent immunotherapy if driver mutation positive?
Published 2 years ago • 29 plays • Length 9:35Download video MP4
Download video MP3
Similar videos
-
1:46
immunotherapy for patients with resectable nsclc & driver mutation-targeted therapies in lung cancer
-
14:57
grace targeted therapies lung cancer 2021 - standards & novel therapies sensitizing mutations, pt 1
-
5:05
grace targeted therapies lung cancer 2021 - changing driver mutation: rebiopsied at progression?
-
11:49
grace targeted therapies lung cancer 2021 - online communities, education & partnership in research
-
2:08
grace targeted therapies lung cancer 2021 - approved therapy for a cdkn2a secondary mutation?
-
2:24
grace targeted therapies lung cancer 2021 - what makes mutations vary?
-
22:49
grace targeted therapies lung cancer 2021 - management of uncommon egfr mutations including exon 20
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
2:05
grace targeted therapies lung cancer 2021 - bypass mechanisms (pik3, mek, erk, etc)
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
2:56
grace targeted therapies lung cancer 2021 - what trials are available for ntrk resistant mutation?
-
3:35
grace targeted therapies lung cancer 2021 - recommended treatment for an alk variant 1 patient
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
14:33
grace targeted therapies lung cancer 2021 - targeted therapies in oligo-metastatic disease
-
21:58
grace targeted therapies lung cancer 2021 - alk therapies-which one comes first, how do we sequence?
-
4:08
grace targeted therapies lung cancer 2021 - wait for ngs panel results - newly diagnosed, 90% pdl1
-
2:01
grace targeted therapies lung cancer 2021 - data learned from ensartinib for ros1 in clinical trial?
-
14:05
grace targeted therapies lung cancer 2021 - standards & novel therapies sensitizing mutations, pt 2